Skip to main content

Highlights: 

  • Delivered revenue for the full year of €169.0 million (US$189.3 million) – an increase of 25% on 2018
  • Full year net profits were €36.2 million ($40.5 million), an increase of 45% on 2018
  • Fourth quarter net revenue of €45.6 million (US$50.8 million) – just above Q3 2019
  • 2019 sales growth triggered the second $20 million milestone payment to Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.)
  • Full year operating profit of €60.9 million (US$68.2 million), an increase of 60% on 2018
  • Cash at year end was €68.6 million ($76.8 million), an increase of €4.2 million from 30 September 2019
  • Cash position at 28 February 2020 after convertible bond issue, initial €5.5 million payment due to Sobi and milestone payment to Bausch Health was €149.2 million ($166.0 million)
     

As with 2017 and 2018, we continued to see consistent growth in the numbers of patients benefiting from RUCONEST® in 2019. As a result of the increase in sales from this growing patient base, we have been able to implement ambitious development plans.

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline